Use of medical foods and nutritional approaches in the treatment of Alzheimer's disease

Clinical Practice

Volumn 9, Issue 2, 2012, Pages 199-209

  Thaipisuttikul, Papan ^a   Galvin, James E ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE OUTCOME; ALZHEIMER DISEASE; DIET THERAPY; DISEASE ASSOCIATION; EVIDENCE BASED MEDICINE; HUMAN; INTERMETHOD COMPARISON; MEDICAL DECISION MAKING; MEDITERRANEAN DIET; MORTALITY; NUTRITIONAL ASSESSMENT; NUTRITIONAL REQUIREMENT; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT SAFETY; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PROFESSIONAL COMPETENCE; PROFESSIONAL KNOWLEDGE; PROFESSIONALISM; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; THERAPY EFFECT;

EID: 84858034620     PISSN: 20449038     EISSN: 20449046     Source Type: Journal    
DOI: 10.2217/cpr.12.3     Document Type: Review

References (64)

1. Ferri CP, Prince M, Brayn C et al. Global prevalence of dementia: a Delphi consensus study. Lancet 366, 2112-2117 (2005).
2. Gauthier S, Cummings J, Ballard C et al. Management of behavioral problems in Alzheimer's disease. Int. Psychogeriatr. 22, 346-372 (2010).
3. Abbott A. Dementia: a problem of our age. Nature 475(7355), S2-S4 (2011).
4. Herrmann N, Chau SA, Kircanski I, Lanctôt KL. Current and emerging drug treatment options for Alzheimer's disease: a systemic review. Drugs 71(15), 2031-2065 (2011).
5. Shah RC. Medical foods for Alzheimer's disease. Drugs Aging 28(6), 421-428 (2011). Provides general concept of medical foods for Alzheimer's disease.
6. Roman MW. Axona (Accera, Inc): a new medical food therapy for persons with Alzheimer's disease. Issues Ment. Health Nurs. 31(6), 435-436 (2010). Summarizes important information about Axona® for the prescriber and patients.
7. Scheltens P, Kamphuis PJ, Verhey FR et al. Efficacy of a medical food in mild Alzheimer's disease: a randomized controlled trial. Alzheimers Dement. 6(1), 1-10.e1 (2010). ■ Provides information on a randomized controlled trial of Souvenaid®.
8. Small GW, Ercoli LM, Silverman DH et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc. Nat. Acad. Sci. USA 97(11), 6037-6042 (2000).
9. de la Torre JC. Cerebral hypoperfusion, capillary degeneration, and development of Alzheimer disease. Alzheimer Dis. Assoc. Disord. 14(Suppl. 1), S72-S81 (2000).
10. Rapoprt SI, Nelson PT. Biomarkers and evolution in Alzheimer disease. Prog. Neurobiol. 95(4), 510-513 (2011).
11. Howland RH. Drug therapies for cognitive impairment and dementia. J. Psychosoc. Nurse Ment. Health Serv. 48(4), 11-14 (2010).
12. Mosconi L, Brys M, Glodzik-Sobanska L, De Santi S, Rusinek H, de Leon MJ. Early detection of Alzheimer's disease using neuroimaging. Exp. Gerontol. 42, 129-138 (2007).
13. Reiman EM, Chen K, Alexander GE et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc. Natl Acad. Sci. USA 101, 284-289 (2004).
14. Seyfried TN, Mukherjee P. Targeting energy metabolism in brain cancer: review and hypothesis. Nutr. Metab. (Lond.) 2, 30 (2005).
15. Van der Auwera I, Wera S, Van Leuven F, Henderson ST. A ketogenic diet reduces amyloid beta 40 and 42 in a mouse model of Alzheimer's disease. Nutr. Metab. (Lond.) 2, 28 (2005).
16. Krikorian R, Shidler MD, Dangelo K, Couch SC, Benoit SC, Clegg DJ. Dietary ketosis enhances memory in mild cognitive impairment. Neurobiol. Aging 33(2), 425.e19-e27 (2010).
17. Henderson ST, Vogel JL, Barr LJ et al. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial. Nutr. Metab. (Lond.) 6, 31 (2009). Provides information on the randomized controlled trial of Axona.
18. Gasser T, Moyer JD, Handschumacher RE. Novel single-pass exchange of circulating uridine in rat liver. Science 213 (4509), 777-778 (1981).
19. Kamphuis PJ, Scheltens P. Can nutrients prevent or delay onset of Alzheimer's disease? J. Alzheimers Dis. 20, 765-775 (2010).
20. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb. Perspect. Med. 3(9), A006189 (2011).
21. Selkoe DJ. Alzheimer's disease is a synaptic failure. Science 298(5594), 789-791 (2002).
22. Knott GW, Holtmaat A, Wilbrecht L, Welker E, Svoboda K. Spine growth precedes synapse formation in the adult neocortex in vivo. Nat. Neurosci. 9(9), 1117-1124 (2006).
23. Pooler AM, Guez DH, Benedictus R, Wurtman RJ. Uridine enhances neurite outgrowth in nerve growth factor-differentiated PC12 [corrected]. Neuroscience 134(1), 207-214 (2005).
24. Kamphuis PJ, Verhey FR, Olde Rikkert MG, Twisk JW, Swinkels SH, Scheltens P. Efficacy of a medical food on cognition in Alzheimer's disease: results from secondary analyses of a randomized, controlled trial. J. Nutr. Health Aging 15(8), 720-724 (2011).
25. Kamphuis PJ, Verhey FR, Olde Rikkert MG, Twisk JW, Swinkels SH, Scheltens P. Effect of a medical food on body mass index and activities of daily living in patients with Alzheimer's disease: secondary analyses from a randomized, controlled trial. J. Nutr. Health Aging 15(8), 672-676 (2011).
26. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 325, 1202 (2002).
27. Casas JP, Bautista LE, Smeeth L, Sharma P, Hingorani AD. Homocysteine and stroke: evidence on a causal link from Mendelian randomization. Lancet 365, 224-232 (2005).
28. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke. JAMA 288, 2015-2022 (2002).
29. Wald DS, Kasturirante A, Simmonds M. Effect of folic acid, with or without other B vitamins, on cognitive decline: meta-analysis of randomized trials. Am. J. Med. 123, 522-527 (2010). Provides the meta-analysis of randomized trials related to the effect of folic acid with or without vitamin B on cognitive decline.
30. Malouf R, Grimeley EJ. Folic acid with or without vitamin B12 for the prevention and treatment of healthy elderly and demented people. Cochrane Database Syst. Rev. 4, CD004514 (2009).
31. Aisen PS, Schneider LS, Sano M et al. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA 300(15), 1774-1783 (2008).
32. Smith AD, Smith SM, de Jager CA et al. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. PLoS ONE 59, e12244 (2010).
33. Guidi I, Galimberti D, Lonarti S et al. Oxidative imbalance in patients with mild cognitive impairment and Alzheimer's disease. Neurobiol. Aging 27(2), 262-269 (2006).
34. Keller JN, Schmitt FA, Scheff SW et al. Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology 64, 1152-1156 (2005).
35. Tamagno E, Guglielmotto M, Monteleone D, Tabaton M. Amyloid-β production: major link between oxidative stress and BACE1. Neurotox. Res. doi:10.1007/s12640-011-9283-6 (2011) (Epub ahead of print).
36. Butterfield DA, Drake J, Pocernich C, Castegna A. Evidence of oxidative damage in Azheimer's disease brain: central role for amyloid beta-peptide. Trends Mol. Med. 7, 548-554 (2001).
37. Vina J, Lloret A, Giraldo E, Badia MC, Alonso MD. Antioxidant pathways in Alzheimer's disease: possibilities of interventions. Curr. Pharm. Des. 17(35), 3861-3864 (2011).
38. Kaneai N, Arai M, Takatsu H, Fukui K, Urano S. Vitamin E inhibits oxidative stress-induced denaturation of nerve terminal protein involved in neurotransmission. J. Alzheimers Dis. 28(1), 183-189 (2011).
39. Hybertson BM, Gao B, Bose SK, McCord JM. Oxidative stress in health and disease: the therapeutic potential of Nrf2 activation. Mol. Aspects Med. 32(4-6), 234-246 (2011).
40. McCaddon A, Hudson PR. L-methylfolate, methylcobalamin, and N-acetylcysteine in the treatment of Alzheimer's disease-related cognitive decline. CNS Spectr. 15(1 Suppl. 1), 2-5 (2010).
41. McCaddon A. Homocysteine and cognitive impairment; a case series in a general practice setting. Nutr. J. doi:10.1186/1475-2891-5-6 (2006) (Epub ahead of print).
42. Ho RC, Cheung MW, Fu E et al. Is high homocysteine level a risk factor for cognitive decline in elderly? A systematic review, meta-analysis, and meta-regression. Am. J. Geriatr. Psychiatry 19(7), 607-617 (2011).
43. Chan A, Paskavitz J, Remington R, Rasmussen S, Shea TB. Efficacy of a vitamin/nutriceutical formulation for early-stage Alzheimer's disease: a 1-year, open-label pilot study with an 16-month caregiver extension. Am. J. Alzheimers Dis. Other Demen. 223, 571-585 (2008).
44. Willett WC, Sacks F, Trichopoulou A et al. Mediterranean diet pyramid: a cultural model for healthy eating. Am. J. Clin. Nutr. 61(6), S1402-S1406 (1995).
45. Sanchez-Villegas A, Delgado-Rodriguez M, Alonso A et al. Association of the Mediterranean dietary pattern with the incidence of depression: the Seguimiento Universidad de Navarra/University of Navarra Follow-up (SUN) Cohort. Arch. Gen. Psychiatry 66(10), 1090-1098 (2009).
46. Knoops KT, de Groot LC, Kromhout D et al. Mediterranean diet, lifestyle factors, and 10-year mortality in elderly European men and women: the HALE project. JAMA 292(12), 1433-1439 (2004).
47. Martínez-González MA, de la Fuente-Arrillaga C, Nunez-Cordoba JM et al. Adherence to Mediterranean diet and risk of developing diabetes: prospective cohort study. BMJ 336(7657), 1348-1351 (2008).
48. Wong A. Incident solar radiation and coronary heart disease mortality rates in Europe. Eur. J. Epidemiol. 23(9), 609-614 (2008).
49. de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 99(6), 779-785 (1999). Provides information on randomized controlled trials on the Mediterranean diet effect.
50. Das DK, Mukherjee S, Ray D. Resveratrol and red wine, healthy heart and longevity. Heart Fail. Rev. 16(4), 425-435 (2011).
51. Scarmeas N, Stern Y, Tang MX et al. Mediterranean diet and risk for Alzheimer's disease. Ann. Neurol. 59, 912-921 (2006).
52. Scarmeas N, Stern Y, Mayeux R et al.Mediterranean diet and mild cognitive impairment. Arch. Neurol. 66, 216-225 (2009).
53. Féart C, Samieri C, Rondeau V et al. Adherence to a Mediterranean diet, cognitive decline, and risk of dementia. JAMA 302, 638-648 (2009).
54. Roberts RO, Geda YE, Cerhan JR et al. Vegetables, unsaturated fats, moderate alcohol intake, and mild cognitive impairment. Dement. Geriatr. Cogn. Disord. 29(5), 413-423 (2010).
55. Sofi F, Cesari F, Abbate R, Gensini GF, Casini A. Adherence to Mediterranean diet and health status: meta-analysis. BMJ 337, A1344 (2008). ■ Provides meta-analysis information on the Mediterranean diet effect.
56. US FDA Medical Foods overview.www.fda.gov/Food/FoodSafety/Product- SpecificInformation/MedicalFoods (Accessed 19 July 2011)
57. US FDA Dietary Supplements.www.fda.gov/food/dietarysupplements/default. htm (Accessed 18 October 2011)
58. Early Memory Loss and Pre Alzheimer's Information from CerefolinNAC® . http://cerefolinnac.com/memory-loss-and-alzheimers-information (Accessed 16 September 2011)
59. Accera Energy Metabolism.www.accerapharma.com/energymetabolism.html (Accessed 19 October 2011)
60. Danone Nutricia Souvenaid® .www.souvenaid.com (Accessed 20 October 2011)
61. Clinical trials on Alzheimer's Disease.www.ctad.fr/07-download/ Congres2011/PressRelease/Friday05112011Pressrelease.doc(Accessed 27 December 2011)
62. Pamlab.www.pamlab.com (Accessed 23 December 2011)
63. MedicineNet Homocysteine.www.medicinenet.com/homocysteine/article.htm (Accessed 19 October 2011)
64. American Heart Association: Homocysteine, Folic Acid and Cardiovascular Disease. www.heart.org/HEARTORG/GettingHealthy/NutritionCenter/Homocysteine- Folic-Acid-and-Cardiovascular-Disease-UCM-305997-Article.jsp (Accessed 19 October 2011)